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Abstract 
The majority of patients with newly diagnosed multiple myeloma (MM) are aged >65 years with 30% 
aged >75 years. Many elderly patients are also vulnerable due to comorbidities that complicate the 
management of MM. The prevalence of MM is expected to rise over time due to an aging population. 
Most elderly MM patients are ineligible for autologous transplantation and the standard treatment has, 
until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, 
bortezomib and lenalidomide, has improved outcomes; however, elderly MM patients are more 
susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-
intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into 
the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for 
vulnerability and an assessment of  cardiac, pulmonary, renal, hepatic and neurological function, as well 
as age >75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to 
be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious non-
hematologic adverse events during treatment should be carefully taken into account to adjust doses and 
optimize outcomes.  
3 
Introduction 
Multiple myeloma (MM) is a malignant disease characterized by uncontrolled plasma tumor cell 
proliferation, driven by intrinsic chromosomal abnormalities and extrinsic stromal cell support, together 
with the presence of monoclonal protein in the blood and/or urine.
1,2
 Typical clinical presentation at 
diagnosis includes anemia (commonly presenting as fatigue), skeletal lesions (presenting as bone pain), 
renal impairment, and hypercalcemia. In Western countries, the annual age-adjusted incidence of MM is 
5.6 cases per 100 000 people. The median patient age at diagnosis is approximately 70 years; only 37% of 
newly-diagnosed patients are aged <65 years, 26% are aged 65-74 years, and 37% are aged ≥75 years.3 
The annual prevalence of MM in patients aged 65-74 years is approximately 31 cases per 100,000 people, 
and it increases to 46 cases per 100,000 people in patients aged ≥75 years. Furthermore, the number of 
elderly patients with MM is likely to increase due to the improved survival times that are associated with 
novel agents coupled with the increasing life-expectancy of the general population. 
In recent years, the introduction of novel agents such as thalidomide, lenalidomide and the 
proteasome inhibitor bortezomib, which are associated with high-dose therapy and autologous stem-cell 
transplantation in young patients and standard chemotherapy in elderly patients, has changed the 
management of myeloma and extended overall survival (OS) times.
4-7
 An estimate of the 5-year relative 
survival of patients with MM in the United States from 1990-1992 to 2002-2004 reported a significant 
survival increase from 29% to 35%. More substantial increases were seen in patients aged <50 years (5-
year relative survival from 45% to 57%) and those aged 50-59 years (5-year relative survival from 39% to 
48%). By contrast, increases were much less pronounced in patients aged 60-69 years (5-year relative 
survival from 31% to 36%), and no improvement was seen in patients aged >70 years (5-year relative 
survival from 27% to 29%) (Figure 1).
3,5,6
 Notably, similar results were observed taking into account life 
expectancy with respect to age, sex and era of diagnosis. In a large population-based cohort study on 
14,381 MM patients diagnosed in Sweden from 1973 to 2003, relative survival ratios, defined as the ratio 
of the observed survival divided by the expected survival, were computed as measures of survival. The 5-
4 
year relative survival ratios improved significantly over the time but the improvement was confined to 
patients  <70 years.
4
  
Many patients aged ≥75 years are vulnerable due to their comorbid conditions that complicate the 
presentation and management of MM. Personalized therapy utilizing dose-adjusted regimens is, therefore, 
urgently needed for these patients. Vulnerable elderly patients are underrepresented in clinical trials
8
 and 
this population is not well studied, despite the fact that the majority of MM diagnoses and related 
mortality occurs in individuals aged >65 years. Further research into the best treatment strategies for 
vulnerable elderly patients with MM is therefore required, including an improved definition of clinical 
vulnerability in the elderly. This review discusses the impact of age and vulnerability on outcomes in MM 
patients, specifically focusing on the effect of these factors on treatment regimens in elderly patients. 
 
Impact of age on multiple myeloma prognosis and response to treatment 
Aging is associated with an increased risk of developing malignancies and the majority of cancer 
diagnoses and deaths occur in people aged >65 years.
3
 The global population is rapidly aging, and the 
number of individuals aged ≥65 years is expected to double between 2000 and 2030. Cancer types for 
which the highest percentage increase in incidence is expected between 2010 to 2030 are stomach (67%), 
liver (59%), MM (57%), prostate (55%), pancreatic (55%), bladder (54%), lung (52%), and colorectal 
(52%).
9
  
Myeloma biology may differ by age at presentation. Ludwig et al analyzed the associations 
between the presenting features and survival times in 1,689 patients with newly diagnosed (ND) MM 
aged <50 years, compared with 8,860 patients aged >50 years. Younger patients were identified as having 
more favorable prognostic features, such as International Staging System and Durie-Salmon stages, and 
fewer adverse prognostic factors including elevated C-reactive protein, low hemoglobin, increased serum 
creatinine, and poor performance status. Younger patients had a significantly longer median survival time 
than those in the older cohort (5.2 years vs 3.7 years, respectively; P<.001). After adjusting for MM-
5 
unrelated mortality, lower International Staging System stage and other favorable prognostic features 
seem to account for the significantly longer survival of younger MM patients.
10
  
There are several factors that may underlie the impact of age on patient prognosis. The human 
aging process is associated with a gradual, progressive decrease in physiological reserve. Changes in body 
composition occur with age (there is a reduction in muscle mass, an increase in body fat, and a reduction 
in intracellular water levels) and all these changes may impact drug metabolism and distribution, but are 
not considered to have a major impact on cancer therapies. More importantly, however, are the age-
related changes that occur in organ function. Aging is associated with clinically-significant reductions in 
renal function, gastric function, hepatic mass and blood flow, bone marrow status, and cardiovascular 
function in elderly patients.
11-14
 All of these changes may affect the pharmacokinetics and 
pharmacodynamics of drugs, altering clinical efficacy and potentially increasing toxicity. Age-related 
organ function and metabolic changes can, therefore, contribute to the poor tolerability of cancer 
treatments seen in elderly patients due to an increase in treatment-related adverse events (AEs). Reduced 
tolerability and reduced dose-intensity lead to the poorer outcomes observed in elderly cancer patients.  
 
The impact of vulnerability on cancer outcome in elderly patients 
Traditionally, the Karnofsky Performance scale or the World Health Organization scores are used to 
determine the fitness of cancer patients, but the role of performance status as unique marker of functional 
status needs to be revised. In elderly patients with or without cancer, three terms are commonly used 
interchangeably to describe vulnerable adults: frailty; comorbidity (or multiple chronic conditions); and 
disability. However, in geriatric medicine, there is a growing consensus that these are distinct clinical 
entities that are causally related. Frailty, comorbidity, and disability all occur individually and commonly 
among elderly patients, and each of these factors has clinical importance. Moreover, it is becoming 
increasingly clear that these three factors are interrelated and have a cumulative effect on the health and 
prognosis of elderly patients (Figure 2). The use of score tables established in geriatric medicine provides 
additional information to performance status: 9% to 38% of elderly patients with good performance status 
6 
(<2) were partially or fully dependent on others to carry out ordinary activities, such as household tasks 
and personal care.
15,16
 
Frailty 
Frailty is a distinct entity recognized by clinicians, with many possible manifestations and no single 
symptom or sign that is itself sufficient or essential for a diagnosis.
17
 A phenotype of the clinically frail 
elderly adult was recently defined, based on the presence of a critical  mass of ≥3 core elements of frailty: 
weakness; poor endurance; weight loss; low physical activity; and slow gait speed. The presence of frailty 
has been identified as an independent predictor of disability and other adverse outcomes in elderly 
adults.
18
 The differing degrees of frailty are outlined in Table 1.  
Comorbidity 
The formal definition of comorbidity is the concurrent presence of two or more medically diagnosed 
diseases in the same individual, with the diagnosis of each contributing disease based on established, 
widely recognized criteria.
17
 Many prognostic indices for the elderly that incorporate age and/or 
comorbidity are available;
19-21
 the Charlson comorbidity index is the one most frequently used in cancer 
patients.
19,22
 However, this is complex and a more simple score index for comorbidities in MM is needed. 
The Charlson index is a summary measure of 19 comorbid conditions weighted 1-6 corresponding to 
disease severity. This gives a total score ranging from 0-37. It can be adapted to account for increasing 
age, adding 1 point to the score for each decade over the age of 50 years. With this index, the relative risk 
of death that can be attributed to an increase of 1 point in the comorbidity score is equivalent to an 
additional decade of age.
19
 With aging, the incidence of comorbid conditions increases markedly, largely 
because the frequency of individual chronic conditions rises with age. As a result, 35% of men and 45% 
of women aged 60-69 years in the US have ≥2 comorbid conditions; this percentage increases 
dramatically to 53% of men and 70% of women by age 80 years.
23
 Comorbidity is associated with 
polymedication and increased risk of drug interactions. 
 
 
7 
Disability 
Disability (which can include both physical and mental impairments or limitations) can be defined as 
difficulty or dependency in carrying out activities essential to independent living, including both essential 
personal care and household tasks, and activities that are important to maintain an individuals’ quality of 
life.
24,25
 Physical disability is common among elderly adults and is more common in elderly women than 
men. The major causes of physical disability in the elderly are chronic diseases such as cardiovascular 
disease, stroke, arthritis, and, in myeloma patients, orthopedic problems plus pain,
26
 highlighting the 
interrelationship between disability and comorbidity. The incidence of disability rises steadily with age 
among those aged ≥65 years.25 Of community-dwelling adults, 20-30% of those aged >70 years report 
some disability in mobility, tasks essential to household management (eg, shopping, meal preparation, 
managing money), and basic self-care tasks (eg, washing, dressing, eating). Disability, independent of its 
causes, is associated with a higher risk of mortality;
27
 disabled adults are more likely to become 
hospitalized.
26,28
 
 
The impact of comorbidity on cancer outcomes 
No data are currently available on the impact of vulnerability on outcomes in MM patients, but the issues 
relating to comorbidity and cancer treatment are discussed in the following section in relation to elderly 
cancer patients in general.  
An observational cohort study of 17,712 patients receiving treatment for multiple cancer types 
suggested that the severity of comorbidities affected survival outcomes in a progressive manner, 
independent of cancer stage.
29
 This observation was supported by several studies where comorbidities 
were associated with a higher risk of mortality.
30-35
  
Comorbid conditions have rarely been systematically studied among hematological patients. 
However, a large population-based study of 1,708 patients with myelodysplastic syndromes (MDS) 
demonstrated that those patients with MDS and comorbid conditions had a significantly higher risk of 
death than those without comorbidities. The risk was found to increase with an increasing number of 
8 
comorbid conditions and, therefore, a higher Charlson score (hazard ratio [HR] for death =1.19 for 
patients with a Charlson index of 1-2; and HR=1.77 for patients with a Charlson index ≥3).36 Wang et al 
also reported that MDS patients with congestive heart failure or chronic obstructive pulmonary disease 
have significantly shorter survival times than their counterparts without those conditions, whereas 
diabetes does not appear to have an impact on survival in patients with MDS. Another study involving 
998 elderly patients with acute leukemia or MDS supported these findings on the impact of comorbidity 
and identified several factors associated with poor outcome, including age ≥75 years, a longer duration of 
prior hematological disorder, and abnormal organ function.
37
 
 
The relationship between age and vulnerability in multiple myeloma 
Although there is evidence for the separate prognostic importance of age, comorbidity, frailty, and 
disability for health outcomes, it is also important to note that many patients have two or more of these 
factors, and that this has a cumulative, adverse impact on their prognosis. The frequently used Charlson 
index has been described above, but another prognostic index has also been successfully developed for 
assessment of post-hospitalization mortality risk in elderly patients aged >70 years. This utilizes the 
combined impact of age, physical disability (determined by levels of dependency in activities in daily 
living), and levels of comorbidity.
20
  
Studies in geriatric oncology populations, including patients with prostate, lung and ovarian 
cancer, have also demonstrated the combined effects of age, comorbidity, frailty, and disability on patient 
prognosis.
38-40
 In a large prospective trial involving 427 patients with cancer (over half of whom had 
hematologic malignancies), age, severe comorbidities, functional impairment, and tumor type were all 
found to be independently related to shorter survival times.
41
 Similarly, in the setting of colorectal 
carcinoma, a model developed as part of a Surveillance, Epidemiology, and End Results (SEER) registry 
review utilized comorbidity and age in addition to gender and disease stage in a model to predict early 
mortality.
33
 The number of comorbid conditions a patient had was found to significantly predict early 
mortality. 
9 
In hematologic oncology, data on the combined impact of vulnerability and age are limited. As discussed 
earlier, a series of MDS patients aged ≥66 years identified comorbidity (assessed using the Charlson 
comorbidity index) as a significant predictor of mortality. A comorbidity index developed specifically for 
patients undergoing hematopoietic cell transplantation was found to have high sensitivity and was 
effective in predicting outcomes in patients with acute myeloid leukemia.
42
 A retrospective analysis of 
968 adults with acute myeloid leukemia was designed to assess the biology of the condition change with 
patient age. In this analysis, elderly patients presented more frequently with poorer performance status 
and with unfavorable cytogenetics. In particular, the combination of poor performance status and 
advanced age identified a group of patients who were highly likely to die within 30 days of starting 
induction therapy.
43
 Unfortunately, however, similar data addressing the prognostic impact of age and 
vulnerability in patients with MM are not currently available. 
 
Clinical treatment of elderly patients with multiple myeloma 
Standard treatment regimens for newly-diagnosed elderly patients (≥65 years) 
NDMM patients aged >65 years are generally considered ineligible for autologous stem-cell 
transplantation as they are physically unable to withstand toxicity of the procedure, although this 
considerably differs from patient to patient, and melphalan dose reduction may allow even patients >70 
years to undergo transplantation. Standard frontline treatment for elderly, transplant-ineligible patients 
has, until recently, been the alkylating agent melphalan in combination with prednisone (MP). This 
regimen is well tolerated in vulnerable elderly patients and is associated with good response rates and 
survival outcomes that are comparable with other conventional combinations of chemotherapy.
44,45
 
However, the availability of novel agents, including the immunomodulatory agents thalidomide and 
lenalidomide, and the proteasome inhibitor bortezomib, has led to the development of new treatment 
options for NDMM patients.
46
 These novel agents can be used in combination with MP as well as in other 
treatment combinations, such as lenalidomide with low-dose dexamethasone.
47-51
  
 
10 
Melphalan plus prednisone versus combination melphalan, prednisone, and thalidomide  
Six randomized studies have compared the efficacy and safety of the standard MP regimen with the new 
combination of MP plus thalidomide (MPT).
48-50,52-55
 These studies reported improved clinical response 
rates and a longer progression-free survival (PFS) associated with MPT compared with MP, but the effect 
of MPT on OS was unclear (Table 2).
47-58
 However, a recent meta-analysis of data from 1,682 patients in 
the six randomized studies of MPT versus MP has confirmed a significant improvement in PFS and a 
trend towards significant improvement in OS when thalidomide is added to MP as a front-line treatment 
in elderly NDMM patients.
59
 MPT was associated with better 1-year overall response rate (ORR; 59% 
with MPT vs 37% with MP) and prolonged PFS (median, 20 months with MPT vs 15 months with MP; 
P<.0001). The thalidomide regimen also led to a 17% risk reduction of death compared with MP 
(HR=0.83; 95% confidence interval [CI], 0.73-0.94; P=.004) and an increased median OS time of 6.6 
months.
59
 This improvement was less pronounced in patients aged ≥75 years. In the Nordic study, the 
median PFS of these patients was shorter compared with patients aged 65-74 years (10 months with MPT 
vs 6 months with MP) and no improvement was observed in OS.
52
 Similar results have been reported in 
the Myeloma IX study using thalidomide in combination with the alternative alkylating agent, 
cyclophosphamide, and steroid, dexamethasone.
60
 
The most common grade 3-4 non-hematologic AEs associated with MPT were peripheral 
neuropathy (6-23%), thromboembolism (3-12%), infections (10-13%), cardiac complications (2-7%), and 
gastrointestinal events (about 5%). Thalidomide discontinuation due to AEs varied from 33-45%.
61
 Some 
studies reported a doubling of early toxic deaths among patients aged ≥75 years and no favorable effect of 
thalidomide on OS in patients with higher World Health Organization performance status.
52,54
 
 
Melphalan plus prednisone versus combination bortezomib, melphalan, and prednisone 
Bortezomib is effective and well tolerated in patients with relapsed or refractory MM.
62,63
 The clinical 
value of adding bortezomib to the standard MP regimen (VMP) was explored in the Velcade as Initial 
Standard Therapy (VISTA) study.
47,56
 ORR in patients treated with VMP was higher compared with the 
11 
MP regimen (80% vs 56%, respectively; P<.001). Similarly, a higher proportion of these patients 
achieved a complete response compared with the MP regimen (30% vs 4%, respectively; P<.001); time-
to-progression was also prolonged (24 vs 16.6 months, respectively; P<.001). Importantly, OS was 
significantly extended in the VMP regimen (HR=0.61; P=.008).
47
 These results have been confirmed by 
an extended follow-up of the VISTA study. After a median follow-up of 36.7 months the risk of death 
associated with the VMP regimen was 35% lower than with MP (HR=0.653; P<.001). Median survival 
time was not reached in the VMP regimen compared with 43 months in the MP regimen.
56
 Also in the 
VISTA study, outcomes were worse in patients aged ≥75 years; within the VMP group, the 3-year OS 
was longer among patients aged <75 years (74%) compared with patients aged ≥75 years (55%).56 Similar 
results both for efficacy and safety were observed in a US community-based phase 3b study comparing 
VMP with bortezomib-dexamethasone and with bortezomib-thalidomide-dexamethasone.
64
 
The incidence of any grade 3-4 hematologic and non-hematologic AEs with VMP was 91%, 
leading to a bortezomib discontinuation rate of 34%. Neutropenia (40%) is the main AE associated with 
VMP, followed by thrombocytopenia (37%), peripheral neuropathy (14%), infections (10%), and 
gastrointestinal events (7%).
47,56
 The recent update of the VISTA study showed that the rate of severe 
AEs was higher in the first four cycles when a twice-weekly bortezomib schedule was administered; it 
was lower during the last five cycles when the lower-dose-intensity once-weekly bortezomib schedule 
was administered.
56
 Two subsequent studies showed that a once-weekly schedule significantly reduced 
the incidence of any grade 3-4 hematologic and non-hematologic AEs, in particular peripheral neuropathy 
(7-8%), as well as the rate of discontinuation due to toxicity.
65,66
 This improvement in safety was obtained 
without negatively impacting on outcomes because although the cumulative planned-dose was lower in 
the once-weekly group (46.8 vs 67.6 mg/m
2
), the cumulative delivered-dose of bortezomib was similar in 
the two groups (39.4 mg/m
2
 in the once-weekly and 40.1 mg/m
2
 in the twice-weekly group; 
Table 3).
47,51,57,65,66
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Melphalan plus prednisone versus combination melphalan, prednisone, and lenalidomide followed by 
continuous lenalidomide treatment  
The IMiD
®
 immunomodulatory compound lenalidomide has demonstrated efficacy in patients with 
relapsed or refractory MM,
67,68
 and has also been evaluated in combination with MP as a frontline 
treatment for NDMM patients.
58
  
Initial results of the randomized trial comparing the addition of lenalidomide to MP followed by 
lenalidomide maintenance treatment (MPR-R) with standard MP (MM-015 study) indicate that MPR-R 
was superior to the standard MP regimen.
58
 The ORR was significantly higher with MPR-R compared 
with MP (77% vs 50%, respectively; P<.001). Complete response rates were also significantly higher 
with MPR combination therapy (16% vs 4%; P<.001). After a median follow-up of 21 months, MPR-R 
led to gains on PFS and reduced the risk of disease progression by 58% compared with MP alone 
(HR=0.423; P<.001). Median PFS was 31 months in the MPR-R regimen compared with 14 months for 
MPR and 13 months for MP, the 2-year PFS was significantly higher in patients who received 
lenalidomide continuous therapy compared with fixed duration MP (55% vs 16%, respectively; P<.001). 
The importance of continuous lenalidomide therapy on outcomes is elucidated by a landmark analysis of 
PFS in patients completing induction therapy and proceeding onto maintenance therapy. This 
demonstrated a 75% reduced risk of disease progression with continuous lenalidomide therapy versus no 
treatment (P<.001; HR=0.245; 95% CI, 0.126-0.476). However, no differences in OS have been reported, 
likely due to the short duration of follow-up to date, the administration of lenalidomide at relapse, and 
possibly more resistant relapses.
58
 Preliminary analysis indicates that outcomes may be worse in patients 
aged ≥75 years, possibly explained by the lower relative dose-intensity of MPR that these patients 
received during induction therapy. In patients aged 65-74 years, MPR alone was superior to MP in terms 
of PFS (HR=0.675; P=.030), but this advantage was not evident in patients aged ≥75 years. Hence, the 
MPR toxicity profile was excessive for frail patients and negatively affected efficacy. The main grade 3-4 
hematologic and non-hematologic AEs associated with MPR were neutropenia (52-71%), 
thrombocytopenia (23-38%), infections (10%), and thromboembolism (5%).
58,69
 In the first 9 cycles of 
13 
therapy, the discontinuation rate due to AEs was 4% in the MP group among patients aged 65-74 years 
and 8% in patients aged ≥75 years. The discontinuation rate due to toxicity was 12% in the MPR or MPR-
R group among patients aged 65-74 years, and 19% in patients aged ≥75 years. The cumulative dose 
intensity was similar in MP and MPR or MPR-R patients aged 65-74 years (97% and 88%, respectively), 
whereas it was reduced in patients aged ≥75 years (97% and 56%, respectively).58 These data clearly 
show that the intended dose-intensity is well maintained in the MP group, is adequate for the MPR 
regimens in patients aged 65-74 years, and is totally unmaintained in those aged ≥75 years. Thus, further 
dose reduction to keep the patient on therapy is needed.  
 
Lenalidomide and dexamethasone  
In NDMM patients, lenalidomide in combination with high-dose dexamethasone (RD) has been shown to 
improve PFS and ORR rates compared with high-dose dexamethasone monotherapy.
70
 However, RD was 
associated with an increased incidence of thromboembolic complications so an adapted regimen of 
lenalidomide with low-dose dexamethasone (Rd) was evaluated.
51
 ORR was lower with Rd (70%) 
compared with RD (81%). The higher response rates for the high-dose dexamethasone regimen did not 
translate into superior PFS (median, 25.3 months in the Rd group vs 19.1 months in the RD group). The 
Rd regimen was associated with significantly improved 1-year OS compared with RD (96% vs 87%, 
respectively; P=.0002) and treatment-related toxicity was also significantly reduced. Similar results were 
observed when the analysis was restricted to 248 patients who did not receive transplant.
51
 
These data indicate that the Rd regimen is an effective regimen for newly diagnosed patients with 
acceptable toxicity. Although the advantages associated with Rd compared with RD were also confirmed 
in a subgroup of patients aged >70 years, inferior outcomes were observed in this subset of patients; the 
ORR was 74% with Rd and 75% with RD. Median PFS was 22 months in the low-dose dexamethasone 
group compared with 16 months in the high dose group, and OS was improved in the low-dose 
dexamethasone regimen (3-year OS, 73% in the Rd group vs 61% in the RD group).
71
  
14 
The incidence of any grade 3-4 non-hematologic AEs was 35% with Rd and 52% with RD, and 
the respective discontinuation rate due to AEs was 19% and 27%, respectively. Deep-vein thrombosis or 
pulmonary embolism were the most frequent toxicities, and were reported in 12% of patients in the Rd 
group and 26% in the RD group; infection was another common AE (9% with Rd and 16% with RD).
51
 
The advantages of Rd over RD were more pronounced in patients aged >70 years due to the poor 
tolerability, higher toxicity profile, and higher mortality rate associated with the high-dose dexamethasone 
in this population. In these patients, the incidence of any grade 3-4 non-hematologic AE increased to 59% 
in the Rd regimen and 78% in the RD regimen.
71
 A phase II trial in relapsed/refractory patients showed 
that lower doses of lenalidomide (15 mg) plus low dose dexamethasone (40 mg weekly) significantly 
reduced the incidence of hematologic toxicities (from 15-30% to 2-13%), infections (from 20% to 8%), 
and thromboembolism (from 20% to 5%).
72
  
Evidence is now emerging that maintenance/continuous therapy with novel agents such as 
thalidomide,
73-75
 lenalidomide,
58,76,77
 or bortezomib
57,65
 is improving PFS with a potential to improve OS. 
However, in elderly patients it is particularly important to start treatment at a dose that can be tolerated 
over the long-term. 
 
Tolerability of novel antimyeloma treatment in elderly patients 
Although the novel agents offer important improvements in survival for patients with MM, the incidence 
of grade 3-4 AEs are significantly higher with combination regimens based on novel agents than with 
traditional chemotherapy regimens (Table 3). This is reflected in the discontinuation rates due to AEs in 
regimens containing novel agents (13-45% across studies). Elderly patients with MM are more 
susceptible to AEs associated with treatments, with 42-53% of elderly patients experiencing grade 3-4 
AEs in the early cycles of treatment with a novel agent.
48-50,52,78
  
Drug-related treatment complications are prevalent among elderly or vulnerable MM patients and 
may lead to premature treatment discontinuations or lower dose intensities. Therefore, to reduced 
treatment efficacy it is crucial that these are anticipated and managed accordingly. This highlights the 
15 
need for dosing strategies to improve the tolerability of treatment with the novel antimyeloma agents, 
especially during induction therapy, in vulnerable, elderly patients to allow for long-term 
treatment. Furthermore, the tolerability of treatment could be improved with supportive therapy, 
particularly in elderly patients. Granulocyte colony-stimulating factors decrease or prevent neutropenia. 
Aspirin or low-molecular-weight heparins should be used to decrease the risk of thromboembolic events 
when immunomodulatory compounds are given. Erythropoiesis-stimulating agents can be used to treat 
chemotherapy-associated anemia with iron supplements improving the effectiveness of treatment. Bone 
pain requires systemic analgesia, local measures, and chemotherapy. Local radiotherapy is effective for 
palliation of bone pain, and bisphosphonates can reduce new bone lesions, pathologic fractures, and 
hypercalcemia. Appropriate hydration, urine alkalinization, rapidly acting therapy for myeloma, and 
treatment of hypercalcemia, hyperuricemia and infections prevent further deterioration of renal function 
in patients with renal impairment.  
In the context of treatment tolerability and individualized treatment strategies, it is also important 
to consider the management of elderly MM patients with relapsed, or relapsed and refractory disease. 
These patients are exposed to multiple sequential lines of treatment, which are likely to have a 
progressive weakening effect on their overall physical condition. Therefore, treatment strategies for 
elderly patients should have minimal cumulative toxicity across the lines of treatment. These should not 
exacerbate any pre-existing conditions such as peripheral neuropathy, which commonly develops as an 
adverse effect of treatment with thalidomide or bortezomib. Supportive therapies, dose adjustments, 
clinical vigilance, and patient education are important to minimize AEs and maintain compliance with 
antimyeloma treatment.  
 
Tailored therapy for the treatment of elderly multiple myeloma patients 
The age-related changes in physiology combined with comorbid conditions, disability, and/or frailty have 
important implications for the treatment of cancer patients. However, in MM patients treatment should 
not be withheld solely on the basis of age. A patient’s overall physical condition and organ function 
16 
should be assessed in order to determine their ability to tolerate treatment. Elderly NDMM patients 
should, therefore, be assessed for frailty, comorbidity, and disability. Cardiac performance, pulmonary 
and hepatic function, renal function (especially in elderly patients determined with creatinine clearance), 
and peripheral neuropathy should be evaluated. Based on the results of these tests it is possible to stratify 
patients into those suitable for full-dose therapy or combination drug treatment, and those requiring 
adjusted-dose treatment strategies (Table 4). We propose recommendations whereby patients with ≥1 risk 
factor (age ≥75 years, frailty, comorbidities, disability, or grade 3-4 non-hematologic AEs), should be 
considered for a reduced-dose treatment strategy. Patients without risk factors should be administered 
full-dose treatment.
46,79
 Recommended starting doses and dose-adjustments according to age groups and 
vulnerability status are presented in Table 4. When a grade 3 or 4 AE occurs during treatment, therapy 
should be discontinued until the toxicity has resolved, usually by the start of the next cycle, at which point 
treatment can be restarted at a lower dose (Table 4). Modifying drug doses at the start of treatment or to 
manage AEs is important as it improves tolerability. Treatment should be interrupted and changed in 
patients not responding after ≥3 cycles, whereas continuous long-term therapy beyond best response may 
be important for sustained disease control of the residual disease in MM.
57,58,65
  
 
Conclusions 
Advanced age and patient vulnerability have a significant and cumulative impact on survival outcomes 
and treatment efficacy in patients with cancer. In MM, elderly patients have a worse prognosis from 
initial diagnosis than those aged <65 years. Currently, the improvements in survival associated with the 
novel antimyeloma agents have not been observed in elderly patients.  
No data are available that assess screening for vulnerability before choosing and starting therapy 
for MM. However, although no data are available specifically for patients with MM due to the 
underrepresentation in clinical trials of elderly adults and patients with comorbidities, it is reasonable to 
translate data on elderly general population to the MM population. We can, therefore, speculate that the 
continued poor prognosis of elderly MM patients may be attributable, at least in part, to physical 
17 
vulnerability and the impact that this has on patients’ ability to tolerate complex treatment regimens. It is, 
therefore, important to consider the age, physical condition, and comorbidity status for all elderly MM 
patients when planning treatment. Appropriate dose-adjustments or use of modified treatment regimens 
should be made accordingly in order to improve the tolerability of treatment. Well tolerated regimens are 
likely to reduce the need for treatment interruptions and thereby should optimize treatment efficacy.  
 Future trials should address the role of age, comorbidities, and geriatric assessment by stratifying 
MM patients into treatment groups at different risk of mortality. In addition to greater inclusion of 
vulnerable elderly patients in standard trial protocols, trials that address specific needs in elderly adults 
(eg, renal impairment) may also yield important insights. To promote the enrolment of elderly adults in 
clinical trials it may be necessary to relax standard protocol eligibility criteria by focusing on developing 
therapeutics suitable for patients with comorbid conditions. Clinical trials focused on optimizing MM 
treatment regimens for both fit and unfit elderly adults are urgently needed. The data from such trials, 
when available, will eventually lead to tailored, ‘personalized’ therapy for elderly MM patients and 
thereby improve OS in this large patient group. 
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Table 1. Levels of frailty and disability in elderly patients and related description. 
Frailty grade Description 
Very fit Active, energetic patients, who exercise regularly or occasionally 
Moderately fit Patients not regularly active beyond routinely walking 
Vulnerable Patients who can perform limited activities but yet do not need help from other people 
Mildly frail Patients who need help for household tasks (shopping, walking several blocks, managing 
their finance, and medications) 
Moderately frail Patients who need partial help for their personal care (dressing, bathing, toileting, eating) 
Severely frail Patients completely dependent from other people for their personal care 
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Table 2. Outcomes from randomized phase 3 clinical trials of different treatment regimens in elderly NDMM patients  
Regimen Median 
age, years 
Dosing CR rate, 
% 
Median 
PFS, 
months 
Median 
OS, 
months 
Discontinuation 
rate, % 
Non-hematologic 
grade 3-4 AEs, 
% 
MPT
48 
69 M: 0.25 mg/kg days 1-4 
P: 40 mg/m
2
 days 1-7 
T: 400 mg/day for twelve 6-week cycles 
13 28 52 45 42 
MPT
49,50 
72 M: 4 mg/m
2
 days 1-7 
P: 40 mg/m
2
 days 1-7 for six 4-week cycles 
T: 100 mg/day until relapse 
16 22 45 34 55* 
MPT
52 
72 M: 0.25 mg/kg 
P: 1 mg/kg days 1-5 
T: 200 mg/day for eight4-week cycles, 
followed by50 mg/day until relapse 
23
† 
13
‡ 
40 36 50 
MPT
53 
78 M: 0.2 mg/kg days 1-4 
P: 2 mg/kg days 1-4 
T: 100 mg/day for twelve 6-week cycles 
7 24 44 42 NA 
MPT
54 
74 M: 0.25 mg/kg days 1-4 13 15 29 32 40 
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Regimen Median 
age, years 
Dosing CR rate, 
% 
Median 
PFS, 
months 
Median 
OS, 
months 
Discontinuation 
rate, % 
Non-hematologic 
grade 3-4 AEs, 
% 
P: 100mg/day days 1-4for 6-week cycles 
until plateau 
T: 400 mg/day until plateau, reduced to 
200 mg/day until progression 
MPT
55 
69 M: 9 mg/m
2
 days 1-4 
P: 60 mg/m
2
 days 1-4 
T: 100 mg/day for eight 6-week cycles, 
followed by100 mg/day until relapse 
9 21
§
 26 16 NA 
VMP
47,56 
71 V: 1.3 mg/m
2
 days1, 4, 8, 11, 22, 25, 29, and 
32 for first four 6-week cycles; days 1, 8, 
15, and 22 for subsequent five 6-week 
cycles 
M: 9 mg/m
2
 days 1-4 
P: 60 mg/m
2
 days 1-4 
30 NA Not 
reached 
34 91* 
VMP
57 
71 V: 1.3 mg/m
2
 days 1, 4, 8, 11, 22, 25, 29, and 24 23  Not 17 33 
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Regimen Median 
age, years 
Dosing CR rate, 
% 
Median 
PFS, 
months 
Median 
OS, 
months 
Discontinuation 
rate, % 
Non-hematologic 
grade 3-4 AEs, 
% 
32 during cycles 1-4; days 1, 8, 15, and 
22 during cycles 5-9 for nine 6-week 
cycles 
M: 9 mg/m
2
 days 1-4 
P: 60 mg/m
2
 days 1-4 
reached 
MPR-R
58 
NA M: 0.18 mg/kg days 1-4 
P: 2 mg/kg days 1-4 
R: 10 mg days 1-21for nine 4-week cycles 
R: 10 mg/day until relapse 
16 31  Not 
reached 
14
¶ 
NA 
Rd
51 
66 R: 25 mg days 1-21 
D: 40 mg days 1-4, 9-12, 17-20  
or 
d: 40 mg days 1, 8, 15, 22 in 4-week cycles 
4 25 Not 
reached 
19 NA 
VMPT
57 
71 V: 1.3 mg/m
2
 days 1, 4, 8, 11, 22, 25, 29, and 
32 during cycles 1-4; days 1, 8, 15, and 
38 Not 
reached 
Not 
reached 
23 46 
30 
Regimen Median 
age, years 
Dosing CR rate, 
% 
Median 
PFS, 
months 
Median 
OS, 
months 
Discontinuation 
rate, % 
Non-hematologic 
grade 3-4 AEs, 
% 
22 during cycles 5-9 
M: 9 mg/m
2
 days 1-4 
P: 60 mg/m
2
 days 1-4 
T: 50 mg daily for nine 6-week cycles 
CR indicates complete response; PFS, progression-free survival; OS, overall survival; AE, adverse event; MPR-R, melphalan, prednisone, and lenalidomide 
followed by lenalidomide maintenance; NA, not available; Rd, lenalidomide plus low-dose dexamethasone; VMP, bortezomib, melphalan, and prednisone; 
VMPT, bortezomib, melphalan, prednisone, and thalidomide. 
*Both hematologic and non-hematologic AEs. 
†
CR plus very good partial response (CR alone not available). 
‡
Event-free survival. 
§
Disease-free survival. 
¶
Including both patients who received lenalidomide maintenance and those who did not. 
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Table 3. Outcome of newly diagnosed patients treated with full-dose or reduced-dose regimens 
 Any grade 3-4 
AEs, % 
Discontinuation rate 
due to toxicity, % 
PFS OS 
Standard dose therapies 
VMP
47
  91 3 50% at 2 years 68% at 3 years 
RD
51
 52 27% 48% at 2 years 78% at 2 years 
Lower dose therapies 
VMP
57,65
 51 12-17 46-50% at 3 years 74-87% at 3 years 
Rd
51
 35 19 52% at 2 years 88% at 2 years 
AE indicates adverse event; PFS, progression-free survival; OS, overall survival,; RD lenalidomide plus high-dose 
dexamethasone; Rd, lenalidomide plus low-dose dexamethasone. 
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Table 4. Treatment algorithm for elderly frail patients (adapted from Palumbo A and Anderson 
K
46
).  
Risk factors 
 Age over 75 years 
 Mild, moderate or severe frailty:  
           patients needing help for household tasks and personal care* 
 Comorbidities: 
      cardiac dysfunction 
      pulmonary dysfunction  
      hepatic dysfunction 
      renal dysfunction 
 
GO-GO MODERATE-GO SLOW-GO 
No risk factors 
 
DOSE LEVEL 0 
At least one risk factor 
 
 
 
DOSE LEVEL −1 
At least one risk factor plus 
occurrence of grade 3-4 non-
hematologic AE 
 
 
DOSE LEVEL −2 
 
Agent 
 
DOSE LEVEL 0 DOSE LEVEL −1 DOSE LEVEL −2 
Dexamethasone 
40 mg/d 
d 1,8,15,22 / 4 wks 
20 mg/d 
d 1,8,15,22 / 4 wks 
10 mg/d 
d 1,8,15,22 / 4 wks 
 
Melphalan 
0.25 mg/kg or 9 mg/m
2
 
d 1-4 / 4-6 wks 
0.18 mg/kg or 7.5 mg/m
2
 
d 1-4 / 4-6 wks 
0.13 mg/kg or 5 mg/m
2
 
d 1-4 / 4-6 wks 
 
Thalidomide 
100 mg/d 
 
50 mg/d 
 
50 mg qod 
 
Lenalidomide 
25 mg/d 
d 1-21 / 4 wks 
15 mg/d 
d 1-21 / 4 wks 
10 mg/d 
d 1-21 / 4 wks 
 
Bortezomib 
1.3 mg/m
2 
twice weekly  
d 1,4,8,11 / 3 wks 
1.3 mg/m
2
 once weekly 
 d 1,8,15,22 / 5 wks 
1.0 mg/m
2
 once weekly 
d 1,8,15,22 / 5 wks 
 
Prednisone 
60 mg/m
2
 d 1-4 or 
50 mg qod 
30 mg/m
2
 d 1-4 or 
25 mg qod 
15 mg/m
2
 d 1-4 or 
12.5 mg qod 
 
Cyclophosphamide 
100 mg/d  
d1-21/ 4 wks or 
300 mg/m
2
/d 
  d 1,8,15 / 4 wks 
50 mg/d 
d 1-21 / 4 wks or 
150 mg/m
2
/d 
 D 1,8,15 / 4 wks 
50 mg qod 
d 1-21 / 4 wks or 
75 mg/m
2
/d  
 d 1,8,15 / 4 wks 
* Details reported in Table 1 
AE denotes adverse event; d, day; wk, week; qod, every other day 
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Figure legends 
Figure 1. Five-year relative survival rates according to the year of diagnosis and the patients’ age at 
diagnosis. Survival rates have increased over the past 35-years in all patient age groups, a trend attributed 
to the impact of novel agents such as thalidomide, bortezomib, and lenalidomide; however, significant 
increases in survival have only been observed in patients aged <65 years at initial diagnosis.
3
  
 
Figure 2. The interrelationship between the three components of vulnerability (comorbidity, frailty, 
and disability) and the major healthcare implications associated with each factor. 
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